For a decade, CAR-T cell therapy has been defined by its role in oncology — reprogramming a patient's own T cells to hunt and destroy blood cancers such as certain lymphomas and leukemias. That chapter may now be giving way to a broader one. Kyverna Therapeutics announced this week that it intends to seek FDA approval for a personalized CAR-T therapy targeting stiff person syndrome (SPS), a rare neurological autoimmune condition marked by progressive muscle rigidity and debilitating spasms. If the agency grants clearance following a planned mid-year submission, the therapy would become the first CAR-T product approved for an autoimmune disease of any kind.
SPS affects a small patient population and has long lacked a dedicated, approved treatment. Current management typically relies on symptom control — benzodiazepines, immunoglobulin infusions, and other immunosuppressive approaches that moderate the disease without addressing its underlying mechanism. Kyverna's approach is mechanistically different: the engineered T cells are designed to deplete B cells, which are the primary producers of the autoantibodies driving the autoimmune attack. Early study results presented this week indicated that the therapy significantly reduced disability in treated patients, suggesting the possibility of a durable reset of the immune system rather than ongoing suppression.
From oncology to autoimmunity
The migration of CAR-T technology from cancer to autoimmune disease has been building for several years. Academic groups, particularly in Germany, have published case reports and small studies using CD19-targeted CAR-T cells in patients with systemic lupus erythematosus, inflammatory myopathy, and systemic sclerosis. Those early efforts demonstrated that B-cell depletion via engineered T cells could produce deep and sometimes sustained remissions in autoimmune conditions — results that conventional B-cell-depleting antibodies had not reliably achieved. The distinction appears to lie in the depth of depletion: CAR-T cells can pursue B cells into tissue niches that monoclonal antibodies reach less effectively.
Kyverna's move toward a regulatory filing represents a shift from academic proof-of-concept to commercial-scale development. That transition carries its own set of challenges. CAR-T manufacturing remains complex, patient-specific, and expensive. In oncology, the therapies carry list prices that often exceed several hundred thousand dollars per treatment. Whether payers and health systems will accept similar economics for autoimmune indications — particularly rare ones — is an open question. The calculus may differ from cancer: autoimmune diseases are chronic, and the cumulative cost of lifelong immunosuppression, hospitalizations, and lost productivity can be substantial. A one-time therapy that durably resets the immune system could, in theory, alter that cost trajectory.
The competitive and regulatory landscape
Kyverna is not alone in pursuing autoimmune applications for cell therapy. Several other companies have disclosed programs targeting lupus, multiple sclerosis, and myasthenia gravis using various cell-engineering platforms. The competitive landscape is forming quickly, and the FDA's handling of Kyverna's submission will set important precedents — both for the evidentiary standards required and for the regulatory pathway that subsequent autoimmune cell therapies will follow.
Safety considerations will be central to that evaluation. In oncology, CAR-T therapies are associated with cytokine release syndrome and neurotoxicity, risks that are accepted in the context of life-threatening cancers. The risk-benefit calculus shifts when the target population has a chronic but not immediately fatal condition. Regulators will need to weigh the severity of SPS — which can be profoundly disabling — against the acute and long-term safety profile of the therapy.
The broader significance extends beyond any single product. If CAR-T therapy proves viable in autoimmune disease, it opens a conceptual door: the immune system becomes not just a weapon to be aimed at tumors, but a system to be reprogrammed when it turns against the body. The distance between that concept and routine clinical practice remains considerable. Manufacturing scale, cost, durability of response, and long-term safety data all stand between the current moment and widespread adoption. What Kyverna's filing does establish is that the hypothesis has matured enough for a company to stake a regulatory bet on it — and for the FDA to be asked, for the first time, whether a CAR-T therapy belongs in the autoimmune medicine cabinet.
With reporting from STAT News.
Source · STAT News (Biotech)
